\begin{sidewaystable}
\begin{tabular}{ l  c  c  c  c  c  c  c  c | c  c | c l l }%14 columns
\multicolumn{1}{l}{} & \multicolumn{8}{c}{\textbf{Drug target-related analysis}} & 
                     \multicolumn{2}{c}{\textbf{\specialcell{Valid-\\ation}}} & \multicolumn{1}{c}{}
                      &  & \\ \cmidrule(r){2-9} \cmidrule(r){10-11}
     \multicolumn{1}{l}{\textbf{Pathogen}} & 
     \multicolumn{1}{c}{\rotatebox[origin=l]{90}{Gene/reaction essentiality}} & 
     \multicolumn{1}{c}{\rotatebox[origin=l]{90}{Minimal media prediction}} & 
     \multicolumn{1}{c}{\rotatebox[origin=l]{90}{Conditional essentiality}} & 
     \multicolumn{1}{c}{\rotatebox[origin=l]{90}{Synthetic lethality}} & 
     \multicolumn{1}{c}{\rotatebox[origin=l]{90}{Flux variability analysis}} & 
     \multicolumn{1}{c}{\rotatebox[origin=l]{90}{Enzyme robustness}} & 
     \multicolumn{1}{c}{\rotatebox[origin=l]{90}{Metabolite essentiality}} & 
     \multicolumn{1}{c}{\rotatebox[origin=l]{90}{Correlated reaction sets}} & 
     \multicolumn{1}{c}{\rotatebox[origin=l]{90}{Literature derived}} & 
     \multicolumn{1}{c}{\rotatebox[origin=l]{90}{Novel experimental validation~}} &
     \multicolumn{1}{c}{\rotatebox[origin=l]{90}{Novel compounds identified}} & 
     \multicolumn{1}{l}{\textbf{Disease}} & \textbf{Refs} \\ %\cline{2-12}
\textit{Acinetobacter baumannii} &
     \cellcolor[gray]{0.8} & & & & & & \cellcolor[gray]{0.8} &  
     & \cellcolor[gray]{0.8} & & & Opportunistic; cepacia syndrome & [24] \\ \cline{2-12}
\textit{Burkholderia cenocepacia} &
     \cellcolor[gray]{0.8} & & \cellcolor[gray]{0.8} & & & & &  
     & \cellcolor[gray]{0.8} & & & Opportunistic; nosocomial infection & [55] \\ \cline{2-12}
\textit{Francisella tularensis} &
     \cellcolor[gray]{0.8} & & \cellcolor[gray]{0.8} & & 
     \cellcolor[gray]{0.8} & \cellcolor[gray]{0.8} 
     & &  & \cellcolor[gray]{0.8} & \cellcolor[gray]{0.8} 
     & & Tularemia & [21] \\ \cline{2-12}
\textit{Haemophilus influenzae} & 
     \cellcolor[gray]{0.8} & \cellcolor[gray]{0.8} & & \cellcolor[gray]{0.8} & 
     & & & & \cellcolor[gray]{0.8} & & 
     & Otitis media and respiratory infections & [8,9] \\ \cline{2-12}
\textit{Helicobacter pylori} & 
     \cellcolor[gray]{0.8} & \cellcolor[gray]{0.8} & 
     \cellcolor[gray]{0.8} & \cellcolor[gray]{0.8} & 
     & & & & \cellcolor[gray]{0.8} & & 
     & Gastritis; peptic ulceration; gastric cancer & [56,57] \\ \cline{2-12}
\textit{Klebsiella pneumoniae} & 
      & & & & & & & & & \cellcolor[gray]{0.8} 
      & & Klebsiella pneumonia; urinary tract infection & [58] \\ \cline{2-12}
\textit{Mycobacterium tuberculosis} & 
     \cellcolor[gray]{0.8} & & \cellcolor[gray]{0.8} 
     & \cellcolor[gray]{0.8} & 
     \cellcolor[gray]{0.8} & \cellcolor[gray]{0.8} 
     & & \cellcolor[gray]{0.8} & \cellcolor[gray]{0.8} & \cellcolor[gray]{0.8} 
     & & Meningitis; meningococcal septicemia & [1,2,19] \\ \cline{2-12}
\textit{Neisseria meningitidis} & 
      & \cellcolor[gray]{0.8} & & & & 
      & & & & \cellcolor[gray]{0.8} & 
      & Opportunistic; cepacia syndrome & [59] \\ \cline{2-12}
\textit{Porphyromonas gingivalis} & 
     \cellcolor[gray]{0.8} & \cellcolor[gray]{0.8} & & & 
     & & & & \cellcolor[gray]{0.8}  & & 
     & Periodontal disease & [17] \\ \cline{2-12}
\textit{Pseudomonas aeruginosa} &
     \cellcolor[gray]{0.8} & & & & & & &  
     & \cellcolor[gray]{0.8} & & & Opportunistic; nosocomial infection & [47] \\ \cline{2-12}
\textit{Salmonella} Typhimurium &
     \cellcolor[gray]{0.8} & & & \cellcolor[gray]{0.8} & 
     \cellcolor[gray]{0.8} & & &  
     & \cellcolor[gray]{0.8} & \cellcolor[gray]{0.8} 
     & & Gastroenteritis; diarrhea & [60-62] \\ \cline{2-12}
\textit{Staphylococcus aureus} & 
     \cellcolor[gray]{0.8} & \cellcolor[gray]{0.8} & & \cellcolor[gray]{0.8} & 
     & & & & \cellcolor[gray]{0.8} & \cellcolor[gray]{0.8} & 
     & Opportunistic; nosocomial infection & [63-65] \\ \cline{2-12}
\textit{Vibrio vulnificus} & 
      & & & & & & \cellcolor[gray]{0.8} & & \cellcolor[gray]{0.8} & \cellcolor[gray]{0.8} 
      & \cellcolor[gray]{0.8} & Bubonic, pneumonic, and septicemic plague & [25] \\ \cline{2-12}
\textit{Yersinia pestis} & 
     \cellcolor[gray]{0.8} & \cellcolor[gray]{0.8} & & \cellcolor[gray]{0.8} & 
     & & & & \cellcolor[gray]{0.8} & & 
     & Opportunistic; nosocomial infection & [66] \\ \cline{2-12}
\textit{Cryptosporidium hominis} & 
     \cellcolor[gray]{0.8} & & & & 
     & & & & \cellcolor[gray]{0.8} & & 
     & Cryptosporidiosis & [67] \\ \cline{2-12}
\textit{Leishmania major} & 
     \cellcolor[gray]{0.8} & \cellcolor[gray]{0.8} & & \cellcolor[gray]{0.8} & 
     & \cellcolor[gray]{0.8} & & & \cellcolor[gray]{0.8} & & 
     & Leishmaniasis & [18] \\ \cline{2-12}
\textit{Plasmodium falciparum} & 
     \cellcolor[gray]{0.8} & & & \cellcolor[gray]{0.8} & 
     & & & & \cellcolor[gray]{0.8} & \cellcolor[gray]{0.8} & \cellcolor[gray]{0.8}
     & Malaria & [37,68] \\ \cline{2-12}
\textit{Trypanosoma cruzi} & 
     \cellcolor[gray]{0.8} & & & & \cellcolor[gray]{0.8}
     & & & & \cellcolor[gray]{0.8} & &
     & Chagas disease & [69] \\ %\cline{2-12}
\end{tabular}
\label{trends:table1}
\caption[Drug targeting-related analysis of pathogen metabolic networks]{
          Drug targeting-related analysis of pathogen metabolic networks}
\end{sidewaystable}